- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
| 14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
| 14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
| 14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 365 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 144 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech | ||
| 29.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.11.24 | Inhibikase Therapeutics files for secondary offering of common stock | 3 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 | 2 | Seeking Alpha |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 163,40 | +3,03 % | ABBVIE mit Prognosesenkung | Der Biopharmakonzern rechnet mit Zusatzkosten in Höhe von 248 Mio. $ im Zusammenhang mit Übernahmen, darunter Meilensteinzahlungen sowie F&E-Aufwendungen. Hintergrund ist der strategische Fokus auf... ► Artikel lesen | |
| TEVA | 13,000 | +0,39 % | Teva Aktie: Zukunftsaussichten sprachlos | Die Teva-Aktie verzeichnet deutliche Gewinne, während Analysten uneins über die zukünftige Bewertung sind. Neue Medikamente könnten den Aufschwung unterstützen. Die Aktie des Pharmaherstellers Teva... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,914 | +2,85 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| BAUSCH HEALTH | 4,729 | -1,67 % | Bausch Health Companies Inc.: Bausch Health Announces Launch of Solta Medical's Fraxel FTX | The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference LAVAL, QC / ACCESS Newswire / April 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global,... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,008 | -0,63 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 5,900 | -3,28 % | Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor | TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Kevin Malone... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,200 | -8,30 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 96,10 | +0,31 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,216 | +2,18 % | SELLAS Life Sciences Group, Inc.: SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| XORTX THERAPEUTICS | 0,952 | +0,85 % | XORTX Therapeutics Inc.: XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 271,70 | -3,34 % | Citizens JMP reiterates Madrigal stock with $443 target | ||
| BRIDGEBIO PHARMA | 31,350 | -0,73 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 57,40 | +0,70 % | Cantor Fitzgerald sets $80 target on Verona Pharma stock | ||
| ENZON PHARMACEUTICALS | 0,062 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,649 | -7,15 % | Opus Genetics, Inc.: Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases | First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,44 % bei einem Aktienkurs von 2,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
